key: cord-0694134-1li5e5yf authors: Roy, Sreeja; Williams, Clare M.; Furuya, Yoichi title: Detrimental impact of allergic airway disease on live attenuated influenza vaccine date: 2021-07-01 journal: Health Sci Rep DOI: 10.1002/hsr2.272 sha: f978bed9611a457b70d7e898cf26fbc763e05fc1 doc_id: 694134 cord_uid: 1li5e5yf nan To the editor, Historically, live attenuated, as opposed to inactivated, vaccines have been highly successful against many infectious diseases (see Ref. 1 ). However, curiously, seasonal live attenuated influenza vaccines (LAIV) or "Flumist" have not demonstrated superior efficacy when compared to inactivated influenza vaccines (IIV), especially in the past several influenza seasons. 2, 3 This is in striking contrast to animal models in which Flumist consistently exhibits a clear advantage over IIV in inducing not only robust humoral immunity but also cytotoxic T cell immunity, [4] [5] [6] [7] which is believed to be important in crossprotection against mismatched influenza viruses. [8] [9] [10] [11] The reason for this discrepancy between human and animal data is not fully understood, but host factors have been suggested to contribute to highly variable LAIV efficacy. 12 Given that chronic conditions, such as asthma, are highly prevalent among adults, that is, 1 in 13 (7.7%) adults in the United States according to centers for disease control and prevention (CDC), 13 we propose that they can negatively impact vaccine efficacy. To test our hypothesis, we utilized mouse models of allergic airway disease (AAD) to assess LAIV efficacy in asthmatic mice ( Figure 1A ). LAIV-elicited systemic IgG responses were significantly diminished in AAD mice ( Figure 1B ,C). Antibody class switching is a complex process that involves a number of different stimuli. 14 In particular, cytokines are known stimuli that direct antibody isotype switching. For example, the type 1 cytokine IFN-γ drives class switching to IgG2a and the type 2 cytokine IL-4 promotes switching to IgG1. 15 Since mouse models of asthma are known to trigger type 2-biased immune responses, 16, 17 it is plausible that the type 2 cytokine environment in AAD mice is suppressing type 1 immunity-based LAIV. Indeed, analysis of IgG subclasses shows that type 1 immunityassociated IgG2a was downregulated in AAD mice following intranasal (i.n.) LAIV vaccination ( Figure 1B ,C). Consistent with the systemic antibody profile, mucosal IgG and IgG2a antibodies were also suppressed in AAD mice ( Figure 1D ). In addition, mucosal IgA titer was reduced in mice with AAD ( Figure 1D ). We next investigated the protective efficacy of LAIV in AAD vs non-AAD mice. While LAIV-immunized AAD mice were protected against homologous challenge (data not shown), the cross-protective efficacy against heterologous infection was severely compromised ( Figure 1E ). This observation is consistent with our previous report that live influenza virus infection establishes inferior mucosal antibody immunity in AAD mice. 18 Taken together, our results show that AAD is a host-associated factor that can negatively impact LAIV efficacy. Our finding may help explain why LAIV efficacy is highly variable in humans. The implication of our finding is that vaccine research should consider the impact of host factors such as chronic diseases for evaluation of experimental vaccines because the magnitude of interference may differ depending on the vaccine type. It is important to note that LAIV is not recommended for individuals with asthma due to increased incidence of wheezing post LAIV administration. 19, 20 Further, people with severe asthma are often excluded from clinical trials that evaluate LAIV efficacy. Therefore, the use of LAIV among asthmatics has been relatively limited and whether asthma exacerbation has a negative effect on the efficacy of LAIV in humans remains unknown. In addition to asthma, other conditions that induce lung inflammation may also impact the efficacy of LAIV, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. 21 The authors declare no competing interests. The data that support the findings of the study are available from the corresponding author upon request. The results shown are representative of two similar experiments. *P < .05; **P < .01; ****P < .0001 as assessed by student's t-test or ANOVA. E, Forty days after vaccination, the AAD mice or non-AAD mice were infected i.n. with a lethal dose (2 Â 10 4 PFU) of H1N1 PR8 strain. Survival was monitored for 20 days (3-8 mice/group). The data shown is representative of two independent experiments. Survival was analyzed using the Kaplan-Meier log-rank test. **P < .01 https://orcid.org/0000-0001-6856-2737 Live attenuated vaccines: historical successes and current challenges Seasonal effectiveness of live attenuated and inactivated influenza vaccine vaccine effectiveness of live attenuated and inactivated influenza vaccines in children in the United States T-cell-mediated crossstrain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccine Sequential immunization with live-attenuated chimeric hemagglutinin-based vaccines confers heterosubtypic immunity against influenza A viruses in a preclinical Ferret model Cutting edge: rapid boosting of cross-reactive memory CD8 T cells broadens the protective capacity of the Flumist vaccine Aerosol vaccination induces robust protective immunity to homologous and heterologous influenza infection in mice A previously unrecognized H-2D(b)-restricted peptide prominent in the primary influenza A virus-specific CD8(+) T-cell response is much less apparent following secondary challenge Anti-influenza virus cytotoxic T lymphocytes recognize the three viral polymerases and a nonstructural protein: responsiveness to individual viral antigens is major histocompatibility complex controlled Functional analysis of influenza-specific helper T cell clones in vivo. T cells specific for internal viral proteins provide cognate help for B cell responses to hemagglutinin The recovery of mice from influenza A virus infection: adoptive transfer of immunity with influenza virus-specific cytotoxic T lymphocytes recognizing a common virion antigen Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19 Immunoglobulin class-switch DNA recombination: induction, targeting and beyond Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production The immunoglobulin G subclass responses of mice to influenza A virus: the effect of mouse strain, and the neutralizing abilities of individual protein A-purified subclass antibodies The IgG subclass responses induced by wild-type, cold-adapted and purified haemagglutinin from influenza virus A/Queensland/6/72 in CBA/CaH mice Asthma increases susceptibility to heterologous but not homologous secondary influenza Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents Clinical features of patients infected with 2019 novel coronavirus in Wuhan Immune-epidemiological parameters of the novel coronavirus -a perspective Detrimental impact of allergic airway disease on live attenuated influenza vaccine